Search Results - "Julier, Patrick"

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial by Dutton, Susan J, MSc, Ferry, David R, Prof, Blazeby, Jane M, Prof, Abbas, Haider, MRCP, Dahle-Smith, Asa, MBChB, Mansoor, Wasat, PhD, Thompson, Joyce, FRCP, Harrison, Mark, PhD, Chatterjee, Anirban, FRCR, Falk, Stephen, MD, Garcia-Alonso, Angel, MD, Fyfe, David W, MD, Hubner, Richard A, PhD, Gamble, Tina, Peachey, Lynnda, BSc, Davoudianfar, Mina, BA, Pearson, Sarah R, BSc, Julier, Patrick, MSc, Jankowski, Janusz, Prof, Kerr, Rachel, MD, Petty, Russell D, MRCP

“…Summary Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have…”
Get full text

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Kerr, Rachel S, Dr, Love, Sharon, BSc, Segelov, Eva, FRACP, Johnstone, Elaine, PhD, Falcon, Beverly, PhD, Hewett, Peter, FRACS, Weaver, Andrew, MD, Church, David, MRCP, Scudder, Claire, MSc, Pearson, Sarah, BSc, Julier, Patrick, MSc, Pezzella, Francesco, Prof, Tomlinson, Ian, Prof, Domingo, Enric, PhD, Kerr, David J, FRCP

“…Summary Background Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could…”
Get full text

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project by Black, Joanna, Julier, Patrick, Eldridge, Lucy, Barber, Vicki S

“…It is essential that electronic data collection (EDC) systems are both compliant with regulations and the principles of Good Clinical Practice (GCP) to allow…”
Get full text

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) by Abhishek, Abhishek, Boyton, RJ, McKnight, Áine, Coates, Laura, Bluett, James, Barber, Vicki S, Cureton, Lucy, Francis, Anne, Appelbe, Duncan, Eldridge, Lucy, Julier, Patrick, Peckham, Nicholas, Valdes, Ana M, Rombach, Ines, Altmann, Daniel M, Nguyen-Van-Tam, Jonathan, Williams, Hywel C, Cook, Jonathan Alistair

“…IntroductionIt is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The…”
Get full text

Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial by MIDGLEY, Rachel S, MCCONKEY, Christopher C, LANGMAN, Michael J, KERR, David J, JOHNSTONE, Elaine C, DUNN, Janet A, SMITH, Justine L, GRUMETT, Simon A, JULIER, Patrick, IVESON, Claire, YANAGISAWA, Yoko, WARREN, Bryan

“…Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was…”
Get full text

Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer by Kerr, David J, Dunn, Janet A, Langman, Michael J, Smith, Justine L, Midgley, Rachel S.J, Stanley, Andrew, Stokes, Joanne C, Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C

“…In this clinical trial, rofecoxib (25 mg per day) was studied in the prevention of recurrent colorectal cancer. Although the median duration of study treatment…”
Get full text

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS by Rosmarin, Dan, Palles, Claire, Pagnamenta, Alistair, Kaur, Kulvinder, Pita, Guillermo, Martin, Miguel, Domingo, Enric, Jones, Angela, Howarth, Kimberley, Freeman-Mills, Luke, Johnstone, Elaine, Wang, Haitao, Love, Sharon, Scudder, Claire, Julier, Patrick, Fernández-Rozadilla, Ceres, Ruiz-Ponte, Clara, Carracedo, Angel, Castellvi-Bel, Sergi, Castells, Antoni, Gonzalez-Neira, Anna, Taylor, Jenny, Kerr, Rachel, Kerr, David, Tomlinson, Ian

“…Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours. About 35% of patients experience…”
Get more information

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial by Abhishek, Abhishek, Boyton, Rosemary J, Peckham, Nicholas, McKnight, Áine, Coates, Laura C, Bluett, James, Barber, Vicki, Cureton, Lucy, Francis, Anne, Appelbe, Duncan, Eldridge, Lucy, Julier, Patrick, Valdes, Ana M, Brooks, Tim, Rombach, Ines, Altmann, Daniel M, Nguyen-Van-Tam, Jonathan S, Williams, Hywel C, Cook, Jonathan A, Pande, Ira, Seng Tang, Ting, Tran, Gui, Layton, Alison, Price, Elizabeth, Whittam, Lindsay, Venkatachalam, Srinivasan, Hawarden, Ashley, Huws, Gwenan, Pratt, Arthur, Reynolds, Nick J, Walsh, David, Joseph, Theresa, Mathew, Rengi, Oikonomou, Stamatios, Gwynne, Catherine, Crowder, Rory, Saravanan, Vadivelu, Mustafa, Alaa, Tacu, Cristina, Batty, Thomas, George, Emmanuel, Soni, Anushka, Horton, Sarah, Madan, Ayesha, Gaffney, Karl, Lapin, Agnieszka, Bingham, Sarah, Levell, Nick, Lim, Edwin, Gullick, Nicola, Holroyd, Chris, Khalid, Salema, Lwin, May, Green, Mike, Hunt, Laura, Alcorn, Nicola, Ellis, Rob, Hider, Samantha, Hassan, Alaa, Youngstein, Taryn, Douglas, Karen, Ho, Gen Nen, Levasseur, Kirsty, Treacy, Sara, Cheila, Myrto, Pradeep, John, Rhys-Dillon, Ceril, Jones, Catrin

“…Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment…”
Get full text

Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors by Nicum, Shibani, Brooks, Claire E, Wharton, Rose, Boyle, Lucy, Kaye, Stanley B., Gourley, Charlie, Hall, Marcia, Montes, Ana, Pearson, Sarah R, Julier, Patrick, Midgley, Rachel A, Schuh, Anna, Dutton, Susan J.

“…Abstract only TPS5615 Background: BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and…”
Get full text

Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG) by Dutton, Susan J., Blazeby, Jane M., Petty, Russell D., Mansoor, Wasat, Thompson, Joyce, Harrison, Mark, Abbas, Haider, Dahle-Smith, Asa, Chatterjee, Anirban, Falk, Stephen, Garcia-Alonso, Angel, Fyfe, David Walter, Hubner, Richard, Gamble, Tina, Peachey, Lynnda, Harvey, Christine, Julier, Patrick, Jankowski, Janusz, Midgley, Rachel, Ferry, David R.

“…Abstract only 6 Background: There are no randomised trials of 2 nd line chemotherapy for esophageal cancer. The phase III COG trial of gefitinib versus placebo…”
Get full text